Myriad Genetics, Inc., a personalized medicine company, focuses on the development and marketing of predictive, personalized, and prognostic medicine tests worldwide. It discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, diagnose disease, assess the risk of disease progression, and guide treatment decisions across six medical specialties where molecular diagnostics can enhance patient care and lower healthcare costs. Its various molecular diagnostic tests include myRisk Hereditary Cancer, a predictive medicine test for hereditary cancer; BRACAnalysis and BART, sequencing tests for hereditary breast and ovarian cancer; BRACAnalysis CDx sequencing test for use as a companion diagnostic in identifying ovarian cancer patients with deleterious suspected deleterious germline; and Tumor BRACAnalysis CDx sequencing test used to predict DNA damaging agents, such as platinum based chemotherapy agents and poly ADP ribose inhibitors. The company also provides COLARIS sequencing test for colorectal and uterine cancer; COLARIS AP sequencing test for colorectal cancer; Vectra DA protein detection test for assessing the disease activity of rheumatoid arthritis; Prolaris, an RNA expression test for prostate cancer; EndoPredict expression test for breast cancer; myPath Melanoma RNA expression test for diagnosing melanoma; and myPlan lung cancer, an RNA expression test for lung cancer. In addition, it offers biomarker discovery, and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.